Yahoo Finance

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy ...
Nasdaq

Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
Healio

Jasper Therapeutics doses first patient in chronic inducible urticaria study

Please provide your email address to receive an email when new articles are posted on . The phase 1b/2a study, SPOTLIGHT, will evaluate subcutaneous briquilimab for the treatment of chronic inducible ...
CMS Wire

Jasper Launches the Industry's First AI Knowledge Layer Built Specifically for Marketing

Jasper furthers its leadership in AI marketing with its new proprietary Brand IQ and Marketing IQ technologies, delivering enhanced brand control and marketing intelligence to enterprise marketing ...
Yahoo Finance

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...